Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1913 clinical trials
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications

This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.

advanced urothelial carcinoma
immunomodulators
immunostimulant
kidney function tests
melanoma
  • 0 views
  • 05 Aug, 2020
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

The purpose of this phase I/Ib study is to determine the safety profile of NIZ985 (new formulation), and if it can be safely combined with Spartalizumab and to determine the appropriate dose and schedule for further study. Moreover, the study will characterize the pharmacokinetic profiles of NIZ985 as a single …

  • 0 views
  • 16 Feb, 2024
  • 1 location
First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies

ATRC-101-A01 is a first-in-human, Phase 1b, open-label trial to characterize the safety, tolerability, pharmacokinetics (PK), and biological activity of escalating doses of ATRC-101, an engineered, fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally-occurring human antibody.

measurable disease
cancer
blood transfusion
melanoma
ovarian cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and …

sarcoma
gastrointestinal cancer
primary tumor
platelet count
metastatic cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Brief Title: Study of BGB-10188 as Monotherapy and in Combination With Zanubrutinib and Tislelizumab

The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose(RP2D),safety & tolerability of BGB-10188: as monotherapy in participants with mature B-cell malignancies; oin combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma …

b-cell lymphoma
follicular lymphoma
melanoma
ovarian cancer
mantle cell lymphoma
  • 0 views
  • 16 Feb, 2024
  • 4 locations
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a …

biotherapy
biologic therapy
i131 mibg therapy
suicide
neuroblastoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

platelet transfusion
anticancer agents
cytokines
recurrent neuroblastoma
iobenguane
  • 0 views
  • 16 Feb, 2024
  • 83 locations
PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy

The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the progression of the disease..

metastatic melanoma
pembrolizumab
melanoma
nivolumab
dynamic acquisition
  • 0 views
  • 16 Feb, 2024
  • 1 location
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic

The primary purpose of this study is to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domains of health-related quality of life and other areas such as COVID-19 specific psychological distress, and disruptions to health care, finances and social interactions. …

covid-19
social interaction
cancer
psychological distress
  • 0 views
  • 05 Aug, 2020
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic

The primary purpose of this study is to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domains of health-related quality of life and other areas such as COVID-19 specific psychological distress, and disruptions to health care, finances and social interactions. …

  • 0 views
  • 10 Nov, 2022
  • 1 location